NASDAQ 100 % ()
FTSE 100 % ()
DOLLAR INDEX % ()
BTC/USD % ()
EUR/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()
CRUDE OIL % ()

MRNA

MRNA US Stock
$152.86
Open: $132.15 High: $154.55 Low: $130.58 Close: $152.9
Range: 2021-01-25 - 2021-01-26
Volume: 38,622,975
Market: Open
Powered by Finage Stock APIDelayed data
MRNA
  • CEO:
  • Employees:
  • Sector:
  • Industry:
MRNA News
Latest news about the MRNA
  • Johnson & Johnson (JNJ) Surges to All-Time High

    Johnson & Johnson (JNJ) stock has rallied to an all-time high in reaction to a strong quarter and next week's vaccine data release.

    View More →
  • Moderna on Track to Deliver 100 Million Doses of Covid Vaccine This Quarter

    The company also expects to deliver 200 million total doses of its vaccine by the end of the second quarter.

    View More →
  • Moderna Says Covid-19 Vaccine Appears To Protect Against Variants; Shares Jump 12%

    Shares of Moderna spiked 12.2% on Jan. 25 after the biotech company said that laboratory studies suggested that its COVID-19 vaccine should be effective against the emerging variants of the virus. This included the B.1.1.7 and B.1.351 variants, first identified in the UK and South Africa, respectively. Specifically, Moderna (MRNA) found that its COVID-19 vaccine produced neutralizing antibodies against the emerging variants of the virus. In addition, it was found that the current two-dose schedule of the vaccine at a dose of 100 micrograms is expected to be protective against the variants. Stéphane Bancel, CEO of Moderna said, “As we seek to defeat the COVID-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves. We are encouraged by these new data, which reinforce our confidence that the Moderna COVID-19 vaccine should be protective against these newly detected variants,” The study showed a “six-fold” reduction in neutralizing antibodies in the South African virus variant. “Despite this reduction, neutralizing titer levels with B.1.351 remain above levels that are expected to be protective,” Moderna stated. As a result, the pharma and biotech company now intends to develop a new booster mRNA (messenger ribonucleic acid) vaccine against the South African variant of the virus. Furthermore, Moderna will seek to test an additional booster dose of its vaccine that will increase the generation of neutralizing antibodies against the emerging variants of the virus beyond the current primary vaccinations. Following the announcement, Piper Sandler analyst Edward Tenthoff reiterated a Buy and set a price target of $170 on the stock. Tenthoff commented in a note to investors, “Despite the slow vaccination pace, Moderna expects to deliver 200M mRNA-1273 doses in the U.S. by end of Q2, and 600M to 1B doses globally by the end of 2021.” (See MRNA stock analysis on TipRanks) Overall, analysts are cautiously optimistic about the stock and the consensus is a Moderate Buy with 7 analysts recommending a Buy, 7 analysts suggesting a Hold, and 2 analysts recommending a Sell. The average price target of $147.85 implies 0.6% upside potential to current levels. Shares have risen 19.1% in the past month. Related News: F5 Closes $440M Cash Acquisition Of Volterra UPS To Divest Freight Business For $800M; Shares Rise 3% United Airlines Posts Wider-Than-Feared Loss of $1.9B In 4Q; Street Says Hold More recent articles from Smarter Analyst: F5 Closes $440M Cash Acquisition Of Volterra UPS To Divest Freight Business For $800M; Shares Rise 3% Twitter Settles Shareholder Derivative Lawsuits Veoneer Inks Driver Assistance Software Partnership With Qualcomm

    View More →
  • The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna

    The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna

    View More →
  • How Long Will Coronavirus Vaccine Drive Moderna (MRNA) Stock?

    Moderna's (MRNA) progress with coronavirus vaccine development and its approval is driving its share prices for the past year. Will the trend continue?

    View More →
  • Morning Bell With Jim Cramer: Buy the Dip in Ford After Earnings

    Jim Cramer shares stock-market news including Moderna's vaccine against the Covid strain in South Africa, how to trade Ford after earnings and advice for young investors.

    View More →
  • Moderna on track to deliver 200 million doses of its COVID vaccine to U.S. govt by end-June

    Moderna Inc. said Tuesday it is on track to deliver 100 million doses of its COVID-19 vaccine to the U.S. government by end-March and to deliver 200 million doses by end-June. The Cambridge, Mass.-based biotech said it has already delivered more than 30 million doses of the vaccine to the U.S. government. About 10.1 million doses of the vaccine have by now been administered in the U.S., the company said, citing Centers for Disease Control and Prevention data. The vaccine was granted emergency use authorization by the U.S. Food and Drug Administration on Dec. 18, shortly after a separate vaccine developed by Pfizer Inc. and its German partner BioNTech SE won the same authorization. The U.S. government has an option to purchase up to 300 million doses of the Moderna vaccine. The vaccine has also been authorized for use in Canada, Israel, the European Union, the U.K. and Switzerland. Moderna shares were down 1.2% premarket, but have gained 596% in the last 12 months, while the SPDR S&P Biotech ETF has gained 73% and the S&P 500 has gained 17%.

    View More →
  • Moderna says on track to deliver 100 mln COVID-19 vaccine doses by first quarter

    Moderna Inc said on Tuesday it was on track to deliver about 100 million doses of its COVID-19 vaccine to the United States by the end of the first quarter of 2021, with 200 million doses in total available by the end of the second quarter.

    View More →
  • Moderna Provides U.S. COVID-19 Vaccine Supply Update

    Moderna provides U.S. COVID-19 Vaccine supply update.

    View More →
  • Merck Just Scrapped Its Coronavirus Vaccines — Is Merck Stock A Buy?

    Merck stock dipped in late January after the Dow Jones pharmaceutical company scrapped development of two "inferior" coronavirus vaccines. Is Merck stock a buy?

    View More →
  • Pfizer Expects to Deliver Covid Vaccines Quicker Than Expected

    A label change will allow Pfizer to squeeze 20 million more doses from its supply than originally thought.

    View More →
  • Comic: Covid-19 in 2021: Déjà Vu, or the Beginning of the End?

    By Geoffrey Smith

    View More →
  • Why Moderna Stock Soared Today

    Shares of Moderna (NASDAQ: MRNA) jumped 12.2% on Monday after the biotechnology company said its COVID-19 vaccine provides protection against new coronavirus strains first identified in the U.K. and South Africa. Scientists have discovered several new variants of the novel coronavirus that are more contagious -- and potentially more dangerous -- than previous versions. Doctors, in turn, have questioned whether Moderna's vaccine would be effective against the new strains.

    View More →
  • Janet Yellen Confirmed as Treasury Secretary

    • Former Federal Reserve Chairwoman Janet Yellen was confirmed by the Senate to be the first woman to hold the position of Treasury Secretary of the United States. The Senate voted 84-15 in favor of the nomination, which received unanimous approval from the Senate Finance Committee on Friday. In her confirmation hearings last week, Yellen said that lawmakers would need to “act big” to ensure a full recovery from the pandemic.

    View More →
  • Moderna CEO offers a bleak assessment of COVID-19: Virus to stay with the world 'forever'

    While Moderna CEO Stephane Bancel said his company's vaccine remains effective against coronavirus variants, a reoccurring booster shot could be likely.

    View More →
  • Merck Scraps 'Inferior' Covid-19 Vaccines; But Shares Recover From Dip

    Merck stock recovered from a dip Monday after the company scrapped development of two coronavirus vaccines the company said were inferior to already authorized drugs by other pharma players.

    View More →
  • Covid Vaccines: Here's What J&J Has To Do To Undercut Pfizer, Moderna

    Johnson & Johnson is expected soon to release test results for its coronavirus vaccine in a move that could rock vaccine stocks Pfizer and Moderna. Pfizer and Moderna have authorized drugs.

    View More →
  • Dow Pares Big Loss, Nasdaq Hits New High As Apple Stock Rallies Ahead Of Earnings

    Key indexes closed mixed Monday, as the Nasdaq hit a fresh closing high and the Dow Jones Industrial Average trimmed most of a 432-point loss.

    View More →
  • Top Stock Reports for NIKE, Amgen & Morgan Stanley

    Top Stock Reports for NIKE, Amgen & Morgan Stanley

    View More →
  • Moderna CEO: US needs to prepare for fall, COVID-19 resurgence

    Moderna's CEO says the company is launching new studies of COVID-19 vaccines is future-proofing against virus variants.

    View More →